-+ 0.00%
-+ 0.00%
-+ 0.00%

Actuate Therapeutics President, CEO and Director Daniel M. Schmitt Reports Acquisition of $49,999.62 in Common Shares

PUBT·10/29/2026 13:36:50
Listen to the news
Actuate Therapeutics President, CEO and Director Daniel M. Schmitt Reports Acquisition of $49,999.62 in Common Shares
  • Actuate Therapeutics President, CEO and Director Daniel M. Schmitt purchased 140,844 common shares at $0.355 each.
  • His direct common stock holdings increased to 442,560 shares.
  • Schmitt also acquired warrants to purchase 70,422 common shares at an exercise price of $0.45 per share.
  • The warrants are immediately exercisable and expire October 28, 2031.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-008147), on October 29, 2026, and is solely responsible for the information contained therein.